Sponsors seeking to conduct Phase I expansion cohort studies must be prepared to address numerous design, statistical and ethical hurdles inherent in such an approach so that the data can be used to support product registration, a multi-stakeholder group said at a cancer research policy conference Nov. 17.
Traditional clinical trial phases in oncology development are increasingly becoming blurred, leading to more first-in-human trials that are subsequently expanded...